top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval
Alpha Tau Announces Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem...
Mar 5, 2023
Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases
JERUSALEM, March 1, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
Mar 1, 2023
Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event
JERUSALEM, December 13, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the...
Dec 14, 2022
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
JERUSALEM, November 22, 2022 - Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the...
Nov 23, 2022
Alpha Tau to Present at Upcoming November Investor Conferences
JERUSALEM, November 9, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the...
Nov 10, 2022
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society
- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the...
Oct 24, 2022
Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and...
Sep 11, 2022
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer
JERUSALEM, September 1, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation...
Sep 6, 2022
Alpha Tau Medical to Participate in Upcoming September Investor Conferences
JERUSALEM, August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...
Aug 31, 2022
Alpha Tau Medical Announces Second Quarter 2022 - Financial Results and Provides Corporate Update
-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial...
Aug 26, 2022
bottom of page